WebApr 11, 2024 · NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the … WebApr 12, 2024 · Intra-Cellular Therapies stock opened at $58.70 on Wednesday. Intra-Cellular Therapies, Inc. has a 1-year low of $42.01 and a 1-year high of $65.98. The firm has a market capitalization of $5.59 ...
Why Intra-Cellular Therapies Climbed Tuesday The Motley Fool
WebAug 9, 2024 · NEW YORK (AP) _ Intra-Cellular Therapies Inc. (ITCI) on Tuesday reported a loss of $86.6 million in its second quarter. The New York-based company said it had a loss of 92 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 79 cents per share. WebApr 11, 2024 · NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. ITCI, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is … have to pdf exercises
Intra-Cellular Therapies - ITCI News Today - MarketBeat
WebApr 7, 2024 · 3/29/2024 – Intra-Cellular Therapies had its price target raised by analysts at Mizuho from $66.00 to $74.00. They now have a “buy” rating on the stock. 3/16/2024 – Intra-Cellular ... WebSep 30, 2024 · Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 646-440-9333. Burns McClellan, Inc. … WebGet the latest Intra-Cellular Therapies Inc (ITCI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. bosak honda michigan city inventory